TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01529281

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Branch Chain Amino Acid (BCAA)
Description: Supplementation lasted for a total of 12 days; this was based on previous research showing a positive with BCAA supplementation on markers of muscle damage. Participants ingested 10 g, twice per day (morning and evening) of BCAA . The BCAA supplement contained a ratio of 2:1:1 (leucine, isoleucine and valine, respectively). The BCAA was in powder form where each serving was mixed with \~300 ml of water.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - asparmate
Description: Supplementation lasted for a total of 12 days. Participants ingested an equivalent looking volume to 10 g of BCAA, twice per day (morning and evening) of placebo (aspartame based artificial sweetener). The BCAA supplement contained a ratio of 2:1:1 (leucine, isoleucine and valine, respectively). The artificial sweetener was in powder form where each serving was mixed with \~300 ml of water.
Study: NCT01984801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% GSK1940029 gel
Description: 200 mg of the gel will be applied to individual patches by using a spatula

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% GSK1940029 gel
Description: 200 mg of the gel will be applied to individual patches by using a spatula

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% GSK1940029 gel
Description: 200 mg of the gel will be applied to individual patches by using a spatula

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% GSK1940029 gel
Description: 200 mg of the gel will be applied to individual patches by using a spatula

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% GSK1940029 gel
Description: 200 mg of the gel will be applied to individual patches by using a spatula

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% GSK1940029 gel
Description: 200 mg of the gel will be applied to individual patches by using a spatula

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3%/1% vehicle gel only
Description: 200 mg of the gel will be applied to individual patches by using a spatula

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3%/1% vehicle gel only
Description: 200 mg of the gel will be applied to individual patches by using a spatula

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3%/1% vehicle gel only
Description: 200 mg of the gel will be applied to individual patches by using a spatula

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sterile distilled water
Description: 200 µL of the solution will be applied to individual patches by using a pipette or syringe

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sterile distilled water
Description: 200 µL of the solution will be applied to individual patches by using a pipette or syringe

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.5% SLS in sterile distilled water
Description: 200 µL of the solution will be applied to individual patches by using a pipette or syringe

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.1% SLS in sterile distilled water
Description: 200 µL of the solution will be applied to individual patches by using a pipette or syringe

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patch only
Description: Only patch will be applied

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patch only
Description: Only patch will be applied
Study: NCT01431040

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No bowel prep
Description: Participants in this group will have a regular diet and no bowel prep the day prior surgery up until midnight.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clear liquid diet and 2 Fleet's enemas
Description: Participants in this group will receive a clear liquid diet and 2 Fleets enemas in the late afternoon prior to surgery.
Study: NCT02543320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LORETA Neurofeedback Training
Description: Undergo LORETA neurofeedback training
Study: NCT03528369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGS-200-1
Description: CGS-200-1 is a multi-component formulation in which the active ingredient for the intended therapeutic effect is capsaicin at a level of 1% for this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGS-200-5
Description: CGS-200-5 is a multi-component formulation in which the active ingredient for the intended therapeutic effect is capsaicin at a level of 5% for this study.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: CGS-200 Vehicle
Description: CGS-200 Vehicle contains all of the ingredients in CGS-200-1 and CGS-200-5 except for capsaicin.
Study: NCT02543320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01121198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral
Study: NCT00621712

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GamCath® central venous catheter
Description: choice of catheter type

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GamCath Dolphin® Protect central venous catheter
Description: choice of catheter type
Study: NCT01838408

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ez2go Complete
Description: EZ2Go Complete

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LoSo Prep
Description: LoSo Prep ™ Magnesium Citrate plus Bisacodyl Kit Study Arm
Study: NCT04321967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin Paste
Description: 1g of 2% Nitroglycerin paste topical application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dermabond
Description: Topical skin adhesive

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermabond
Description: Topical skin adhesive
Study: NCT04472377

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self sampling kit for collecting discharge from vaginal fornix
Description: A device to collect exfoliative cells from vaginal fornix that can self-operated with ease and comfort.
Study: NCT01550172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Behavioral Therapy A and NHMS
Description: The night home monitoring system provides caregivers with reliable alerts and information regarding the whereabouts of the person with dementia during the night.~Sleep behavioral therapy A uses a combination of cognitive exercises and behavior adjustments.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Behavioral Therapy B and NHMS
Description: The night home monitoring system (NHMS) provides caregivers with reliable alerts and information regarding the whereabouts of the person with dementia during the night.~Sleep behavioral therapy B uses primarily behavioral adjustments.
Study: NCT04380532

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V-SARS
Description: Therapeutic vaccine formulated as a pill derived from heat-inactivated plasma from COVID-19 patients administered once-per-day to at least 20 healthy volunters for at least one month
Study: NCT01893827

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XR-NTX (Extended-Release Naltrexone)
Description: 380mg (4cc) XR-NTX administered by IM injection 1x/month for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Naltrexone (O-NTX)
Description: 50mg pill form of naltrexone taken 1x/day for 6 months.
Study: NCT00656318

Intervention type: OTHER
Intervention: oral contraceptive pill (OCP; OCPs)
Description: Daily administration of oral contraceptive pill for up to 3 months (2 months of daily administration required for the study).

Intervention type: OTHER
Intervention: oral contraceptive pill (OCP; OCPs)
Description: Daily administration of oral contraceptive pill for up to 3 months (2 months of daily administration required for the study).
Study: NCT00449098

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OculusGen Biodegradable Collagen Matrix Implant
Description: Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy with MMC
Description: Trabeculectomy with MMC
Study: NCT01897701

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Avian Influenza VLP (H7N9)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Avian Influenza VLP (H7N9)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Avian Influenza VLP (H7N9)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Avian Influenza VLP (H7N9)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Avian Influenza VLP (H7N9)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Avian Influenza VLP (H7N9)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvant 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvant 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvant 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvant 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03288090

Intervention type: OTHER
Intervention: FSS: Fatigue Severity Scale
Description: Fatigue scale with 9 items rated from 1 to 7, assessing physical fatigue, fatigue in the psychosocial environment and fatigue in general (3 items in each category).

Intervention type: OTHER
Intervention: FSS: Fatigue Severity Scale
Description: Fatigue scale with 9 items rated from 1 to 7, assessing physical fatigue, fatigue in the psychosocial environment and fatigue in general (3 items in each category).

Intervention type: OTHER
Intervention: Neuropsychological evaluation battery
Description: A standardized French neuropsychological battery for the cognitive evaluation of stroke patients.

Intervention type: OTHER
Intervention: Neuropsychological evaluation battery
Description: A standardized French neuropsychological battery for the cognitive evaluation of stroke patients.

Intervention type: OTHER
Intervention: Other functional scores
Description: Rankin Score, Instrumental Activities of Daily Living (IADL) Score, Rivermead Mobility Index (RMI) scale, Hospital Anxiety Depression scale (HAD) scale for depression / anxiety, Stroke Specific Quality of Life scale for quality of life, Quality Index of Pittsburgh Sleep (PSQI), Vertical Analog Visual Scale for Pain and Vertical Digital Visual Scale

Intervention type: OTHER
Intervention: Other functional scores
Description: Rankin Score, Instrumental Activities of Daily Living (IADL) Score, Rivermead Mobility Index (RMI) scale, Hospital Anxiety Depression scale (HAD) scale for depression / anxiety, Stroke Specific Quality of Life scale for quality of life, Quality Index of Pittsburgh Sleep (PSQI), Vertical Analog Visual Scale for Pain and Vertical Digital Visual Scale
Study: NCT04154865

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypercapnia
Description: Eligible subjects will undergo transcranial Doppler assessment before and after hypercapnia exposure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler
Description: A transcranial Doppler ultrasound probe will be used to assess middle cerebral artery velocity to quantify cerebral blood flow at various time points throughout the study visit.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cycle ergometer
Description: A cycle ergometer will be used to acutely increase cerebral blood flow.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Tests
Description: A battery of cognitive tests will be completed by the subject.
Study: NCT04570774

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: rTMS over cerebral motor cortex and cerebellar hemisphere

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: rTMS over cerebral motor cortex and cerebellar hemisphere

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: rTMS over cerebral motor cortex and cerebellar hemisphere

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: rTMS over cerebral motor cortex and cerebellar hemisphere
Study: NCT00909428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin Succinate
Description: Participants take 10mg daily solifenacin succinate for 30 days
Study: NCT01086865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apetiviton BC
Description: Administer the recommended dosage preferably one hour before the main meal:~Children (2 to 6 years): 2.5 mL 3 x daily. Adults (18 to 50 years): 5 mL 3 x daily. Elderly (60 to 80 years): 5 ml 3 x daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apetiviton BC
Description: Administer the recommended dosage preferably one hour before the main meal:~Children (2 to 6 years): 2.5 mL 3 x daily. Adults (18 to 50 years): 5 mL 3 x daily. Elderly (60 to 80 years): 5 ml 3 x daily.
Study: NCT00840255

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BBTI-MV
Description: Twenty participants will be randomized to BBTI-MV. As previously described, the intervention will be delivered over 4 consecutive weeks, which include individual face-to-face visits on Weeks 1 and 3, and telephone appointments on Weeks 2 and 4. Interventions will be delivered at Western Psychiatric Institutes and Clinic. If possible, (according to space availability), the face-to-face sessions may also be conducted at the VAPHS clinics or at Reserve and Veterans Centers locally and regionally to strengthen our relations with local care and services providers and centers, and to facilitate future collaborative efforts. The duration of the first treatment visit is 45-minutes, and the follow-up visit on Week 3 will last no more than 30 minutes. Brief (\<20 minutes) telephone sessions will be conducted on Weeks 2 and 4.

Intervention type: OTHER
Group type: OTHER
Intervention: Information Control
Description: Participants will receive two brochures from the American Academy on Sleep Medicine of Sleep Hygiene and on Insomnia. The therapists will read the content of the 2 brochures with participants, and discuss how the information provide relates to individual participants' sleep experiences. No recommendations for altering sleep schedules will be made by the assigned therapist. Participants will be instructed to read these two brochures over the course of the following week, and to consider how the information provided in the brochures related to their own sleep patterns
Study: NCT04623320

Intervention type: DIAGNOSTIC_TEST
Intervention: euglycaemic clamp test
Description: clamp test (golden standard) to determine insulin resistance

Intervention type: DIAGNOSTIC_TEST
Intervention: euglycaemic clamp test
Description: clamp test (golden standard) to determine insulin resistance

Intervention type: DIAGNOSTIC_TEST
Intervention: 13C glucose breath test
Description: 13C glucose breath test to compare with the golden standard

Intervention type: DIAGNOSTIC_TEST
Intervention: 13C glucose breath test
Description: 13C glucose breath test to compare with the golden standard
Study: NCT02454829

Intervention type: OTHER
Intervention: questionnaire
Description: A questionnaire will be send concerning the patient's ovarian function since the cryopreservation procedure i.e: progression of puberty, menstrual cycle, hormonal treatment, desire for pregnancy, occurence of pregnancy, details of pregnancy, need for ART (Artificial Reproductive Techniques), and about the patient's satisfaction concerning the cryopreservation procedure. Data collected will be correlated with treatments received.

Intervention type: OTHER
Intervention: questionnaire
Description: A questionnaire will be send concerning the patient's ovarian function since the cryopreservation procedure i.e: progression of puberty, menstrual cycle, hormonal treatment, desire for pregnancy, occurence of pregnancy, details of pregnancy, need for ART (Artificial Reproductive Techniques), and about the patient's satisfaction concerning the cryopreservation procedure. Data collected will be correlated with treatments received.

Intervention type: OTHER
Intervention: questionnaire
Description: A questionnaire will be send concerning the patient's ovarian function since the cryopreservation procedure i.e: progression of puberty, menstrual cycle, hormonal treatment, desire for pregnancy, occurence of pregnancy, details of pregnancy, need for ART (Artificial Reproductive Techniques), and about the patient's satisfaction concerning the cryopreservation procedure. Data collected will be correlated with treatments received.

Intervention type: OTHER
Intervention: questionnaire
Description: A questionnaire will be send concerning the patient's ovarian function since the cryopreservation procedure i.e: progression of puberty, menstrual cycle, hormonal treatment, desire for pregnancy, occurence of pregnancy, details of pregnancy, need for ART (Artificial Reproductive Techniques), and about the patient's satisfaction concerning the cryopreservation procedure. Data collected will be correlated with treatments received.

Intervention type: OTHER
Intervention: questionnaire
Description: A questionnaire will be send concerning the patient's ovarian function since the cryopreservation procedure i.e: progression of puberty, menstrual cycle, hormonal treatment, desire for pregnancy, occurence of pregnancy, details of pregnancy, need for ART (Artificial Reproductive Techniques), and about the patient's satisfaction concerning the cryopreservation procedure. Data collected will be correlated with treatments received.

Intervention type: OTHER
Intervention: questionnaire
Description: A questionnaire will be send concerning the patient's ovarian function since the cryopreservation procedure i.e: progression of puberty, menstrual cycle, hormonal treatment, desire for pregnancy, occurence of pregnancy, details of pregnancy, need for ART (Artificial Reproductive Techniques), and about the patient's satisfaction concerning the cryopreservation procedure. Data collected will be correlated with treatments received.
Study: NCT04142502

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol as a sedation drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidin
Description: Dexmedetomidine as a sedation drug
Study: NCT01175889

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-Z Clean ACE Blade
Description: The prospective assessment of the E-Z Clean ACE electrosurgical electrodes using the ACE Blade in the ACE Mode for targeted procedures such as abdominoplasty, bilateral breast reduction, bilateral breast lifts, bilateral brachioplasty, bilateral lateral thigh and buttocks lifts, or any combination thereof.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: E-Z Clean ACE Blade
Description: The prospective assessment of the E-Z Clean ACE electrosurgical electrodes using the ACE Blade in the ACE Mode for targeted procedures such as abdominoplasty, bilateral breast reduction, bilateral breast lifts, bilateral brachioplasty, bilateral lateral thigh and buttocks lifts, or any combination thereof.
Study: NCT01866163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 90100

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study: NCT05102422

Intervention type: DRUG
Intervention: Propofol 1 % Injectable Suspension
Description: Induction and maintenance of general anesthesia using the intravenous anesthetic

Intervention type: DRUG
Intervention: Sevoflurane inhalant product
Description: Induction and maintenance of general anesthesia using the inhaled anesthetic sevoflurane
Study: NCT04280822

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant immunochemotherapy
Description: Neo-adjuvant chemotherapy(cisplatin and paclitaxel):~Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles. JS001, 240mg ivgtt, d3, \>30min, 3week, 2 cycles~Surgery:~2-3weeks after Neo-adjuvant chemotherapy Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.~Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included).~After surgery/ maintain period:~JS001, 240mg ivgtt, d3, \>30min, 3week (8 cycles at most)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant immunochemotherapy
Description: Neo-adjuvant chemotherapy(cisplatin and paclitaxel):~Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles. JS001, 240mg ivgtt, d3, \>30min, 3week, 2 cycles~Surgery:~2-3weeks after Neo-adjuvant chemotherapy Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.~Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included).~After surgery/ maintain period:~JS001, 240mg ivgtt, d3, \>30min, 3week (8 cycles at most)
Study: NCT01689584

Intervention type: GENETIC
Group type: OTHER
Intervention: salivary kit
Description: The saliva samples will be made of selected related (DNA).
Study: NCT02473458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Licorice whole extract
Description: Patients randomly received one of below capsules labeled with codes during the first 24 hours after stroke attack:~1. Starch-filled capsules (as placebo)~2. 450 mg whole licorice extract capsules~3. 900 mg whole licorice extract capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Licorice whole extract
Description: Patients randomly received one of below capsules labeled with codes during the first 24 hours after stroke attack:~1. Starch-filled capsules (as placebo)~2. 450 mg whole licorice extract capsules~3. 900 mg whole licorice extract capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04137614

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drug coated balloon (DCB)
Description: Drug coated balloon (DCB）is a new type of PTA, which could improve the re-stenosis rate significantly.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Digital substraction angiography (DSA)
Description: DSA was used to evaluated the stenosis of renal artery
Study: NCT04152343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RFA Physics Library -- a Planning and Guidance Platform (PGP)
Description: Research software used to support liver RFA of HCC lesions \>2cm